Retinal vein occlusion (RVO) to feature in presentations at upcoming ARVO 2024 conference

(Image credit: AdobeStock/Nanci)

The annual meeting of The Association of Research in Vision and Ophthalmology (ARVO) will take place in Seattle, Washington from May 5 – May 9, 2024. At this event, researchers will present data on a wide variety of topics related to ophthalmology, including retinal vein occlusion (RVO). For those interested in attending presentations on RVO at this meeting, Modern Retina has compiled a list.

On Demand sessions

• Prevalence of retinal vein occlusions in patients taking systemic tyrosine kinase inhibitors
  • Presented by Chandi Duphare, Cleveland Clinic
• Risk of cardiovascular adverse events in retinal vein occlusion patients receiving anti-vascular endothelial growth factor injections
  • Presented by Emily Albrecht, Case Western Reserve University

Sunday, May 5, 2024

• Impact of exposure to residual intraretinal fluid and fluctuations of central subfield thickness on visual outcomes in eyes with macular edema following central retinal vein occlusion: A 1-year post hoc analysis of the COPERNICUS and GALILEO trials
  • 1:00 – 2:45 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0369
• Prevalence of exudative age-related macular degeneration in eyes with central retinal vein occlusion in a large database
  • 3:15 – 5:00 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0332
• Evaluation of microvascular changes in patients with retinal vein occlusion using ultra-wide-field swept-source OCT angiography
  • 3:15 – 5:00 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0633

Monday, May 6, 2024

• Deep Learning Network to Distinguish Between Retinal Vein Occlusion and Diabetic Macular Edema
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: A0245
• Risk factors, treatment, and outcomes in Branch Retinal Vein Occlusion of various sectors of 197 cases with 2-year follow-up.
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: A0050
• Analyzing the Impact of Anti-VEGF Loading Dose Administration on 5-Year Visual Acuity in Patients with Branch Retinal Vein Occlusion
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0053
• Long-term visual prognosis in branch retinal vein occlusion treated for macular edema
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0068
• Canagliflozin Attenuated p40 Gasdermin D-mediated Retinal Glia-Neuron Crosstalk and Inflammatory Cytokine Release in a Mouse Model of Retinal Vein Occlusion
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0069
• The impact of socioeconomic factors on the efficacy of bevacizumab for macular edema secondary to retinal vein occlusion
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0071
• Ethnoracial Representation in US Retinal Vein Occlusion Clinical Trials from 2008-2022
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0072
• Ultrawide Field Fluorescein Angiogram (UWF-FA) Perivascular Leakage in Retinal Vein Occlusion from SCORE2
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0073
• The Relationship of Retinal Vein Occlusion and Open Angle Glaucoma
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0074
• Anatomical parameters of the choroid failed to act as biomarkers for predicting the number of intravitreal injections for branch retinal vein occlusion
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0078
• Nox4 Deficiency Alleviates Iron Overload-induced Ferroptosis in a Mouse model of Retinal Vein Occlusion
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0085
• Diagnostic Utility of GCC and IPL Ratio in Differentiating Branch Retinal Vein Occlusion and Primary Open Angle Glaucoma
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0223
• Evaluating changes in blood volume rate in the main retinal arteries before and after treatment for glaucoma and retinal vein occlusion using Doppler holography.
  • 8:45 - 9:00 am PT
  • Paper session presentation – Tahoma 2 – Seattle Convention Center
  • Presentation number: 1511
• Machine Learning Quantification of Fluid Volume in Eyes with Retinal Vein Occlusion Undergoing Treatment with Aflibercept: The REVOLT study
  • 3:00 – 4:45 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: A0287

Tuesday, May 7, 2024

• Efficacy, safety, and durability of faricimab in macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: A0388
• Does Retinal Vein Occlusion protect against development and progression of Diabetic Retinopathy?
  • 8:30 – 10:15 am PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0478

Wednesday, May 8, 2024

• En face OCT detects rapid progression of epiretinal membrane secondly to branch retinal vein occlusion
  • 10:30 am – 12:15 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0565
• Widerfield Swept Source Optical Coherence Tomography Angiography Metrics as Predictors of Anti-VEGF Treatment in Retinal Vein Occlusion
  • 10:30 am – 12:15 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0579
• Superficial and deep network collaterals on wide field OCT angiography as a predictor of risk of neovascularisation in Branch retinal vein occlusion
  • 2:15 – 4:00 pm PT
    • Poster session in the Exhibit Hall – Seattle Convention Center
• Posterboard Number: B0628

Thursday, May 9, 2024

• Association of anti-VEGF treatment-free interval on long-term visual acuity in patients with branch retinal vein occlusion
  • 11:45 am – 1:30 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0127
• Efficacy and safety of a low dose dexamethasone implant for diabetic macular edema and retinal vein occlusion: Results of the First-In-Human Phase 2 RIPPLE-1 trial
  • 11:45 am – 1:30 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0163
• Differences in Retinal Functional Changes after Anti-VEGF Treatment between Ischemic and Non-ischemic Central Retinal Vein Occlusion
  • 11:45 am – 1:30 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0188
• Central Retinal Vein Occlusion in Younger Individuals Following Intense Exercise
  • 11:45 am – 1:30 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0190
• Anti-VEGF Pretreatment in Patients with History of Retinal Vein Occlusion Protects Against Postoperative Macular Edema Following Cataract Surgery
  • 11:45 am – 1:30 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0191
• NLRP1 Acts as a Negative Regulator of Retinal Ganglion Cell Pyroptosis in a Mouse Model of Retinal Vein Occlusion
  • 11:45 am – 1:30 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0192
• Treatment outcomes with anti-VEGF therapy for retinal vein occlusion: an analysis of real-world data from 16 UK sites
  • 11:45 am – 1:30 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0195
• RETICAD: Quantitative Analysis of Treatment Response in Eyes with Retinal Vein Occlusion
  • 11:45 am – 1:30 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0196
• Vascular Charateristics of Ischemic and Exudative Central Retinal Vein Occlusion
  • 11:45 am – 1:30 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0199
• Subretinal fluid in macular edema secondary to branch retinal vein occlusion
  • 11:45 am – 1:30 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0209
• Pro Re Nata versus treat-and-extend anti-VEGF dosing strategies for the treatment of macular oedema in retinal vein occlusion: 12-month outcomes
  • 11:45 am – 1:30 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0213
• Retinal oxygen kinetics, hemodynamics and ocular movement changes after anti-VEGF in retinal vein occlusion through a multimodal imaging system
  • 11:45 am – 1:30 pm PT
  • Poster session in the Exhibit Hall – Seattle Convention Center
  • Posterboard Number: B0800